NEW YORK – Bristol Myers Squibb (BMS) yesterday announced that the US Food and Drug Administration (FDA) has approved the combination of the immune checkpoint inhibitor drugs nivolumab (Opdivo) and ipilimumab (Yervoy) together with two cycles of platinum-doublet chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer. The treatment combination was approved for patients without EGFR or ALK gene mutations regardless of their PD-L1 status.